文献速递药物不良反应与药物警戒

生物制品可识别性:基于欧盟EudraVigilance可疑药品不良反应报告数据库的分析

Identifiability of Biologicals: An Analysis Using EudraVigilance, the European Union's Database of Reports of Suspected Adverse Drug Reactions.
PubMed 文献 · Clin Pharmacol Ther · 2021-09-26

总体识别率为91.5%,但近5年呈下降趋势,该下降由5种广泛使用的物质驱动,主要见于肿瘤领域。首个生物类似药上市未影响其可识别性。

要点

  • 欧洲ADR报告中生物制品商品名总体识别率为91.5%,但近5年下降。
  • 识别率下降由5种广泛使用物质驱动,主要见于肿瘤领域。
  • 其他生物制品识别率保持稳定(超过90%),首仿上市未影响识别性。

核心结论

  • 欧洲ADR报告中生物制品商品名识别总体稳健且随时间稳定,但少数常用物质的下降趋势需监测以逆转。

主要发现

  • 总体商品名识别率为91.5%,但近5年呈下降趋势。
  • 识别率下降由5种广泛使用物质驱动,主要见于肿瘤领域。
  • 其他生物制品识别率保持稳定(超过90%)。
  • 首个生物类似药上市未影响其可识别性。

关键数值与推荐

  • 总体商品名识别率为91.5%。
  • 其他生物制品识别率保持超过90%。

临床怎么用

  • 临床报告ADR时应准确记录生物制品商品名,以支持产品特异性安全信号监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The relevance of biological therapies for an increasing number of conditions is on the rise. Following the expiry of the initial period of market exclusivity, many of these successful therapies have seen the arrival of biosimilars on the market. The clear identification of the precise medicine responsible for an adverse drug reaction (ADR) report is an important element for pharmacovigilance, allowing timely detection of potential product-specific safety signals. We looked at the identifiability of biologicals up to the level of commercial product name in ADR reports received from European clinical practice between 2011 and December 2019. A good level of identification (91.5%) was observed overall, but at the same time a downward trend was observed in the last 5 years. This reduction in the level of identifiability of biological products (originators and biosimilars) at the commercial name level in general was driven by five widely used substances, whereas the identification of all other biologics stayed consistent over time (at over 90%). We observed that those five substances were used mostly within oncology. The introduction of the first biosimilar in the market did not appear to affect their identifiability. These results show that although the general level of identification at the commercial product name level in ADRs in Europe is robust and generally stable over time, decreasing trends can be down to a few commonly used substances, which need to be monitored to reverse the trend.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Correia Pinheiro L, Giezen TJ, Wolff-Holz E, et al. Identifiability of Biologicals: An Analysis Using EudraVigilance, the European Union's Database of Reports of Suspected Adverse Drug Reactions. Clin Pharmacol Ther. 2021. PMID: 34472087. doi:10.1002/cpt.2411

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。